Definitive Contract W81XWH18C0351
Award Date
4/6/18
Potential Completion Date
9/20/21
Potential Value
$652K
Federal Agency
Medical Command
Awardee
Emergent Travel Health Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
AN97 - R&D- Medical: Other (Commercialized)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Redwood City, CA 94065, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase III Action
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract awarded by the Medical Command division of the U.S. Department of Defense to Emergent Travel Health Inc., a for-profit biopharmaceutical company. The contract, valued at $3,161,941.10, is for a Small Business Innovation Research (SBIR) Phase III action, a non-set-aside contract type. Emergent Travel Health Inc. is providing goods and services related to vaccine stability testing, vaccine development, and vaccine procurement under this definitive, cost-plus-fixed-fee...
This is a Definitive Contract awarded by the U.S. Army Medical Command (MEDCOM) to Emergent Travel Health Inc., a for-profit biopharmaceutical company, for $111,369.51. The contract is for Phase III of a Small Business Innovation Research (SBIR) program action, with an ultimate completion date of April 27, 2016. Emergent Travel Health Inc. has previously provided vaccine stability testing, vaccine development, and vaccine procurement services to federal agencies including the National Institutes...
This is a $2,574,853.28 Firm Fixed Price contract awarded by the Department of the Army Medical Command to Technovax Inc., a Minority Owned, Self Certified Small Disadvantaged Business, for the "Next-Generation Adenovirus Vaccine" under the ARMY 15.1 SBIR (Small Business Innovation Research) program. The contract is set aside for Small Businesses and has a period of performance through March 31, 2023. The contract is associated with the National Interest Action Code for the Coronavirus...
This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services' National Institutes of Health (DHHS NIH) to Janssen Vaccines & Prevention B.V., a foreign-owned, for-profit organization, for the production of adenoviral vector vaccines. The contract has a potential value of $82,806,174.12 and a completion date of September 14, 2011. The contract is not set aside for any specific business type. The award is not associated with a larger vehicle. The contract is...
This is a $762,812,695.00 firm fixed price contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak response plan. The contract...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services, to Profectus Biosciences, Inc., a small business contractor. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $7,524,330.27 and a period of performance through November 30, 2016. The contract is for the GMP (Good Manufacturing Practice) manufacture of the...
This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
This contract award, valued at $37,890,000, was issued by the Centers for Disease Control and Prevention (CDC) to Emergent BioDefense Operations Lansing LLC for the delivery of ACAM 2000 vaccines. ACAM 2000 is the only Food and Drug Administration (FDA)-licensed vaccine for the prevention of smallpox disease, a critical component of the U.S. government's strategic national stockpile. The contract, awarded on September 30, 2015, is a firm-fixed-price delivery order with an ultimate completion...
This is a $99,941,719.80 definitive, firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, on March 16, 2017. The contract has an ultimate completion date of March 15, 2019 and is not set aside. Emergent Biodefense is a for-profit manufacturer of medical countermeasures and biopharmaceuticals, specializing in vaccines and therapeutics for public health...